AI-generated research brief — verify at source
Eptinezumab Plus Patient Education Reduces Monthly Migraine Days in Chronic Migraine With Medication Overuse
In adults with chronic migraine complicated by medication-overuse headache, eptinezumab combined with a brief educational intervention reduced monthly migraine days by 6.9 days from baseline, compared with 3.7 days in the placebo group — a statistically significant difference of 3.2 fewer migraine days per month (95% CI −4.2 to −2.2). The trial met its primary endpoint and all key secondary endpoints, providing Class I evidence that this combination approach is superior to patient education alone in a historically difficult-to-treat population.
What Was Studied
The RESOLUTION trial investigated whether eptinezumab — an intravenous anti-calcitonin gene-related peptide (CGRP) monoclonal antibody used for migraine prevention — could reduce monthly migraine days when combined with a standardized brief educational intervention (BEI) in adults carrying both a chronic migraine and medication-overuse headache diagnosis. The co-occurrence of these two conditions complicates management, making it important to determine whether CGRP-targeting therapies can deliver meaningful benefit even in the presence of medication overuse.
How It Was Studied
The RESOLUTION trial was a phase 4, double-blind, placebo-controlled randomized trial conducted across 76 specialist clinics in 11 countries, enrolling participants between July 2022 and March 2025. A total of 608 adults with confirmed diagnoses of both chronic migraine and medication-overuse headache were randomized 1:1 to receive either eptinezumab 100 mg intravenously plus a brief educational intervention, or placebo intravenously plus the same educational intervention. The primary analysis window was weeks 1–4 post-treatment, with a 12-week placebo-controlled observation period in total. Of the 604 participants who received treatment, 596 (98%) completed the placebo-controlled period, indicating strong study retention. The sample was predominantly female (86%), with a mean age of 45.5 years (SD 12.0).
What Was Observed
- Primary endpoint — monthly migraine days (weeks 1–4): Participants receiving eptinezumab experienced a reduction of 6.9 monthly migraine days from baseline, versus 3.7 days in the placebo group. The between-group difference of 3.2 fewer days favored eptinezumab (95% CI −4.2 to −2.2), representing a clinically meaningful and statistically significant advantage over the first four weeks of treatment.
- Key secondary endpoints — sustained and broad benefit: Eptinezumab was statistically superior to placebo across all multiplicity-controlled key secondary endpoints, which included changes in monthly headache days, monthly days of acute migraine medication use, average daily pain, and the proportions of participants still meeting diagnostic thresholds for chronic migraine and medication-overuse headache. Superiority held throughout the full 12-week observation period, not only at the primary four-week window.
- Early onset of effect: The benefit of eptinezumab was detectable as early as weeks 1–4, suggesting a rapid onset of action even in patients with established medication overuse — a group in whom treatment response is often delayed or attenuated with other approaches.
- Safety and tolerability: Treatment-emergent adverse events were assessed throughout the trial. Eptinezumab was described as generally well tolerated, with no new safety signals identified beyond the established profile of the drug.
Why This Matters
Chronic migraine combined with medication-overuse headache represents one of the more challenging presentations in headache medicine, and robust randomized evidence in this dual-diagnosis population has been limited. By demonstrating Class I evidence of superiority — the highest tier of evidence classification — across both the primary and all key secondary endpoints, this trial directly addresses whether CGRP-pathway inhibition retains its efficacy in the context of medication overuse. The finding that benefit emerged within the first four weeks, and was sustained through 12 weeks, strengthens the case for eptinezumab plus patient education as an integrated treatment strategy for this group.
How to Read This Result
This is a high-quality, adequately powered, placebo-controlled trial with near-complete follow-up and consistent results across primary and secondary endpoints; however, the placebo-controlled period extends only to 12 weeks, so the durability of these benefits beyond that window remains to be established from longer-term data.
Limitations
The abstract does not explicitly report study limitations.